SUPN Supernus Pharmaceuticals, Inc.
Healthcare$48.21-2.37%ClosedMarket Cap: $2.80B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.58
P/S
3.60
EV/EBITDA
61.09
DCF Value
$110.98
FCF Yield
2.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.4%
Operating Margin
-5.4%
Net Margin
-3.7%
ROE
-2.7%
ROA
-1.9%
ROIC
-2.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $207.7M | 88.7% | $-7.4M | $-2.3M | $— | — |
| Q4 null | $211.6M | 89.1% | $13.8M | $-4.1M | $— | — |
| FY null | $719.0M | 89.6% | $-36.9M | $-38.5M | $— | — |
| Q3 null | $192.1M | 90.1% | $-60.2M | $-45.1M | $— | — |
| Q2 null | $165.5M | 89.8% | $12.1M | $22.5M | $— | — |
| Q1 null | $149.8M | 89.5% | $-10.3M | $-11.8M | $— | — |
| Q4 null | $174.2M | 85.0% | $21.4M | $15.3M | $— | — |
| FY null | $661.8M | 88.2% | $81.7M | $73.9M | $— | — |
| Q3 null | $175.7M | 90.0% | $40.8M | $38.5M | $— | — |
| Q2 null | $168.3M | 89.4% | $22.6M | $19.9M | $— | — |
| Q1 null | $143.6M | 88.6% | $-3.2M | $124.0K | $— | — |
| Q4 2023 | $164.3M | 88.1% | $-996.0K | $1.2M | $0.02 | — |